Communique from the Annual General Meeting in Eevia Health Plc
The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the “Company”) was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
1. Annual report and results
The Annual General Meeting adopted the income statement and the balance sheet for the financial year 2021 and resolved that the net loss of 2,635,577.02 EUR – shall be transferred to retained earnings/loss account. No dividends are to be paid.
2. Discharge from Liability
The Annual General Meeting granted the Members of the Board of Directors and the Chief Executive Officer discharge from liability for the management of the Company’s business for the financial year 2021.
3. Election of the Members of the Board of Directors
The Annual General Meeting resolved, for the time until the end of the next Annual General Meeting, to re-elect Martin Bjørklund, Per Benjaminsen, Magne Ruus Simensen, and Johanna Panula, and elect Oskar Wegelius as Members of the Board of Directors. Martin Bjørklund was elected as the Chairman of the Board of Directors.
4. Remuneration to the Board of Directors
The Annual General Meeting resolved that the Chairman shall receive remuneration of EUR 20,000 and that every other Board Member shall receive remuneration of EUR 10,000.
5. Election and remuneration of the Auditor
The Annual General Meeting resolved to re-elect PricewaterHouse Coopers Oy as auditor, with Riitta Ulvinen as the principal auditor. It was resolved that the auditor shall receive remuneration according to the approved invoice.
For further information, please contact:
Gabriella Beni
CFO, Eevia Health Plc
Email: gabriella@eeviahealth.com
Telephone: +358 407 48 8666
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.